Perphenazine

Generic Name
Perphenazine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C21H26ClN3OS
CAS Number
58-39-9
Unique Ingredient Identifier
FTA7XXY4EZ
Background

An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.

Indication

For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.

Associated Conditions
Anxiety, Depression, Schizophrenia, Moderate Agitation, Moderate Anxiety, Moderate Depressed mood, Severe Anxiety, Severe Depressed mood, Severe Nausea and vomiting, Severe agitation
Associated Therapies
-
Clinical Trials
Related News

Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE

First Posted Date
2023-03-09
Last Posted Date
2023-10-19
Lead Sponsor
Maastricht University
Target Recruit Count
28
Registration Number
NCT05762146
Locations
πŸ‡©πŸ‡ͺ

University Hospital Essen, Department of Neurology, Essen, Germany

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

First Posted Date
2020-10-28
Last Posted Date
2024-10-08
Lead Sponsor
Jennifer Holder-Murray
Target Recruit Count
2500
Registration Number
NCT04606264
Locations
πŸ‡ΊπŸ‡Έ

UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States

πŸ‡ΊπŸ‡Έ

UPMC Presbyterian, Pittsburgh, Pennsylvania, United States

πŸ‡ΊπŸ‡Έ

UPMC Passavant, Pittsburgh, Pennsylvania, United States

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
Conditions
Bipolar Disorder
First Posted Date
2016-09-08
Last Posted Date
2024-03-12
Lead Sponsor
University of New Mexico
Target Recruit Count
1037352
Registration Number
NCT02893371
Locations
πŸ‡ΊπŸ‡Έ

Christophe G Lambert, Albuquerque, New Mexico, United States

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

First Posted Date
2015-11-09
Last Posted Date
2019-01-23
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
296
Registration Number
NCT02600741

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

First Posted Date
2015-05-01
Last Posted Date
2021-12-03
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
337
Registration Number
NCT02431702

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
πŸ‡©πŸ‡ͺ

Bezirkskrankenhaus Augsburg, Augsburg, Germany

πŸ‡©πŸ‡ͺ

Krankenhaus HedwigshΓΆhe, Berlin, Germany

πŸ‡©πŸ‡ͺ

Hannover Medical School, Hannover, Germany

and more 2 locations

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

First Posted Date
2014-12-04
Last Posted Date
2018-10-11
Lead Sponsor
Technical University of Munich
Target Recruit Count
21
Registration Number
NCT02307396
Locations
πŸ‡©πŸ‡ͺ

Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar, Munich, Bavaria, Germany

Lurasidone Effects on Tissue Glutamate in Schizophrenia

First Posted Date
2014-07-24
Last Posted Date
2021-03-01
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
35
Registration Number
NCT02199743
Locations
πŸ‡ΊπŸ‡Έ

UT Southwestern Medical Center, Dallas, Texas, United States

Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital

First Posted Date
2010-09-01
Last Posted Date
2013-07-08
Lead Sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Registration Number
NCT01193166

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

First Posted Date
2010-07-07
Last Posted Date
2015-04-24
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
450
Registration Number
NCT01157351
Β© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy